AU2014205356A1 - Controlled release formulations of lorazepam - Google Patents

Controlled release formulations of lorazepam Download PDF

Info

Publication number
AU2014205356A1
AU2014205356A1 AU2014205356A AU2014205356A AU2014205356A1 AU 2014205356 A1 AU2014205356 A1 AU 2014205356A1 AU 2014205356 A AU2014205356 A AU 2014205356A AU 2014205356 A AU2014205356 A AU 2014205356A AU 2014205356 A1 AU2014205356 A1 AU 2014205356A1
Authority
AU
Australia
Prior art keywords
lorazepam
release
pharmaceutical composition
composition according
hours
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2014205356A
Other languages
English (en)
Inventor
Douglas A. Saltel
Michael Vachon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
EDGEMONT PHARMACEUTICALS LLC
Original Assignee
EDGEMONT PHARMACEUTICALS LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50030512&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2014205356(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by EDGEMONT PHARMACEUTICALS LLC filed Critical EDGEMONT PHARMACEUTICALS LLC
Publication of AU2014205356A1 publication Critical patent/AU2014205356A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
AU2014205356A 2013-01-09 2014-01-09 Controlled release formulations of lorazepam Abandoned AU2014205356A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361750792P 2013-01-09 2013-01-09
US61/750,792 2013-01-09
US201361762836P 2013-02-08 2013-02-08
US61/762,836 2013-02-08
PCT/US2014/010863 WO2014110248A1 (en) 2013-01-09 2014-01-09 Controlled release formulations of lorazepam

Publications (1)

Publication Number Publication Date
AU2014205356A1 true AU2014205356A1 (en) 2015-07-30

Family

ID=50030512

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2014205356A Abandoned AU2014205356A1 (en) 2013-01-09 2014-01-09 Controlled release formulations of lorazepam

Country Status (16)

Country Link
EP (1) EP2943186A1 (ko)
JP (1) JP2016504391A (ko)
KR (1) KR20150127037A (ko)
CN (1) CN105188682A (ko)
AU (1) AU2014205356A1 (ko)
BR (1) BR112015016322A8 (ko)
CA (1) CA2897313A1 (ko)
CL (1) CL2015001921A1 (ko)
HK (1) HK1213803A1 (ko)
IL (1) IL239778A0 (ko)
MX (1) MX2015008757A (ko)
PE (1) PE20151431A1 (ko)
PH (1) PH12015501533A1 (ko)
RU (1) RU2015128914A (ko)
SG (1) SG11201505352RA (ko)
WO (1) WO2014110248A1 (ko)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020008756A2 (pt) 2017-11-01 2020-10-13 Edgemont Pharmaceuticals, LLC Trust composições farmacêuticas orais de lorazepam resistentes a álcool

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL298071A (ko) 1963-06-04
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3786813A (en) 1972-12-27 1974-01-22 Alza Corp Drug delivery device with self actuated mechanism for retaining device in selected area
US4361545A (en) 1979-05-21 1982-11-30 Rowell Laboratories, Inc. Solid pharmaceutical formulations for slow, zero order release via controlled surface erosion
JPS61501511A (ja) * 1984-03-21 1986-07-24 アメリカン・ホ−ム・プロダクツ・コ−ポレイション 徐放性医薬カプセル
US4624847A (en) 1985-04-22 1986-11-25 Alza Corporation Drug delivery device for programmed delivery of beneficial drug
US5009895A (en) 1990-02-02 1991-04-23 Merck & Co., Inc. Sustained release with high and low viscosity HPMC
US5945125A (en) 1995-02-28 1999-08-31 Temple University Controlled release tablet
CO5140079A1 (es) * 1998-10-14 2002-03-22 Novartis Ag Composicion farmaceutica de liberacion sostenida y metodo para liberar un agente farmaceuticamente activo de liberacion sostenida y metodo para liberar un agente far- maceuticamente activo
AU2141202A (en) 2000-12-05 2002-06-18 Alexander Macgregor Hydrostatic delivery system for controlled delivery of agent
IL159715A0 (en) 2001-07-10 2004-06-20 Teva Pharma Drug delivery system for zero order, zero order-biphasic, ascending or descending drug delivery
US6703045B2 (en) 2001-08-21 2004-03-09 Council Of Scientific & Industrial Research Composition and method for maintaining blood glucose level
BR0302017B1 (pt) * 2003-06-02 2014-10-29 Ems Sigma Pharma Ltda Composição farmacêutica sublingual a base de um agonista do receptor central de benzodiazepínicos
KR100822519B1 (ko) * 2005-02-15 2008-04-16 주식회사종근당 위장 내에서 제어방출되는 단일 매트릭스 정제

Also Published As

Publication number Publication date
CL2015001921A1 (es) 2015-12-18
BR112015016322A2 (pt) 2017-07-11
JP2016504391A (ja) 2016-02-12
BR112015016322A8 (pt) 2018-01-23
KR20150127037A (ko) 2015-11-16
PE20151431A1 (es) 2015-09-23
PH12015501533A1 (en) 2015-10-05
CN105188682A (zh) 2015-12-23
MX2015008757A (es) 2016-02-05
HK1213803A1 (zh) 2016-07-15
CA2897313A1 (en) 2014-07-17
IL239778A0 (en) 2015-08-31
SG11201505352RA (en) 2015-08-28
RU2015128914A (ru) 2017-02-14
EP2943186A1 (en) 2015-11-18
WO2014110248A1 (en) 2014-07-17

Similar Documents

Publication Publication Date Title
KR101052436B1 (ko) 프라미펙솔 또는 약제학적으로 허용되는 이의 염을함유하는 연장 방출형 정제 제형, 이의 제조방법 및 이의용도
US7943170B2 (en) Sustained release paracetamol containing compositions
US9173848B2 (en) Solid pharmaceutical fixed dose compositions comprising irbesartan and amlodipine, their preparation and their therapeutic application
EA026244B1 (ru) Фармацевтические композиции, содержащие 4-амино-5-фтор-3-[6-(4-метилпиперазин-1-ил)-1h-бензимидазол-2-ил]-1h-хинолин-2-она лактат моногидрат
AU2014299447B2 (en) Pharmaceutical capsule composite formulation comprising tadalafil and tamsulosin
RU2679448C2 (ru) Твердые лекарственные формы, обладающие противорвотным действием, с замедленным высвобождением
MX2012009689A (es) Formulaciones farmaceuticas solidas de ramipril y besilato de amlodipino y su preparacion.
AU2014205356A1 (en) Controlled release formulations of lorazepam
RU2678324C2 (ru) Составы лоразепама с замедленным высвобождением
US20150190345A1 (en) Controlled Release Formulations of Lorazepam
EP2409701B1 (en) Prasugrel granules with improved stability
EP3244880A1 (en) A stable bilayer pharmaceutical tablet compositions comprising fixed dose of irbesartan and amlodipine
US20060222713A1 (en) Extended release pharmaceutical composition of phenytoin sodium

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period